Charles River’s Memphis facility approved to manufacture Vertex’s CASGEVY™ therapy, the world’s first gene-edited therapy targeting severe sickle cell disease
Liberal blood transfusion may reduce recurrence risk, improve survival in heart attack patients with anemia
An international clinical trial led by physician Jeffrey L. Carson, distinguished professor of medicine at Rutgers Robert Wood Johnson Medical School, found that a liberal
November 13, 2023